Immunogenic conjugated polypeptide for treatment of herpes simplex virus
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jun 3, 2003
Grant Date -
N/A
app pub date -
Mar 30, 2000
filing date -
Sep 30, 1997
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
Peptide constructs chemically synthesized to contain a Herpes Simplex Virus specific antigenic peptide, such as, the 322-332 peptide (H1) from the ICP27 protein of Herpes Simplex Virus (HSV-1) and a peptide from a T cell binding ligand (TCBL), such as .beta.-2M (aa 35-50), which elicits a TH1-like response in vitro tests in mice, were protective against challenge with HSV.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully